FindTrial
Sign In

Transit-times of ultrasound contrast agent and flow pattern in sovrahepatic vein: effects of therapy with non selective beta blocker - ND

Transit-times of ultrasound contrast agent and flow pattern in sovrahepatic vein: effects of therapy with non selective beta blocker - ND

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-005654-22-IT
Enrollment
Unknown
Registered
2007-11-14
Start date
2008-04-17
Completion date
Unknown
Last updated
2013-08-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatic cirrhosis MedDRA version: 9.1 Level: LLT Classification code 10019641 Term: Hepatic cirrhosis

Interventions

Trade Name: INDERAL*30CPR 40MG Pharmaceutical Form: Tablet INN or Proposed INN: Propranolol Concentration unit: mg milligram(s) Concentration type: equal Concentration number: 40-

Sponsors

POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: histologic diagnosis of hepatic cirrhosis; hepatic cirrhosis with endoscopic signs of portal hypertension; age > 18 years; informed consent; chronic liver disease with ultrasound signs of portal hypertension; patients in current treatment with propranolol; naïve patients with medical prescription to propranolol Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Contraindication to beta blockers; contraindication to contrast agent Sonovue; thrombosis of splancnic circulation; treatment with others beta blocker; pregnant or breastfeeding women;hepatocellular carcinoma;liver metastases

Design outcomes

Primary

MeasureTime frame
Main Objective: Evaluation of hemodynamic effects of non selective beta blocker by Doppler hepatic vein and with ultrasound contrast agent;Secondary Objective: Prevention of the development of varices in patients with hepatic cirrhosis;Primary end point(s): To assess the flow pattern in hepatic vein and the transit times of Sonovue in hepatic circulation before and after oral admistration of propranolol—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026